Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications
The six transcriptomic immune subtypes (ISs) (C1 - C6) were reported to have complex and different interplay between TME and cancer cells in TCGA (The Cancer Genome Atlas) pan-cancer cohort. Our study specifically explored how the consequence of interplay determines the prognosis and the response to...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.877896/full |
| _version_ | 1811246232926945280 |
|---|---|
| author | Feng Wang Xuan Gao Xuan Gao Peiyuan Wang Peiyuan Wang Peiyuan Wang Hao He Peng Chen Zhentian Liu Yujie Chen Hang Zhou Weijie Chen Xin Yi Xuefeng Xia Shuoyan Liu Shuoyan Liu Shuoyan Liu |
| author_facet | Feng Wang Xuan Gao Xuan Gao Peiyuan Wang Peiyuan Wang Peiyuan Wang Hao He Peng Chen Zhentian Liu Yujie Chen Hang Zhou Weijie Chen Xin Yi Xuefeng Xia Shuoyan Liu Shuoyan Liu Shuoyan Liu |
| author_sort | Feng Wang |
| collection | DOAJ |
| description | The six transcriptomic immune subtypes (ISs) (C1 - C6) were reported to have complex and different interplay between TME and cancer cells in TCGA (The Cancer Genome Atlas) pan-cancer cohort. Our study specifically explored how the consequence of interplay determines the prognosis and the response to therapy in LUAD cohorts. Clinical and molecular information of LUAD patients were from TCGA and Gene Expression Omnibus (GEO). The immune cell populations and gene/pathway enrichment analysis were performed to explore the molecular differences among the C3 IS and other ISs in the LUAD population. The proportion of C3 inflammatory IS was identified as the most common IS in both TCGA (N = 457) and GEO (N = 901) cohorts. The C3 IS was also found to be the most accurate prognostic subtype, which was associated with significantly longer OS (p <0.001) and DFS (p <0.001). The C3 IS presented higher levels of CD8 T, M1 macrophage, and myeloid dendritic cells, while lower levels of M2 macrophages and cancer-associated fibroblast cells. Moreover, the C3 subtype was enriched in the antigen process and presenting, interferon-gamma response, T cell receptor signaling, and natural killer cell-mediated cytotoxicity pathways than C1/C2. In contrast, the C1/C2 presented greater activation of pathways related to the cell cycles, DNA repair, and p53 signaling pathways. The immune-related C3 IS had a great ability to stratify the prognosis of LUAD, providing clues for further pathogenic research. This classification might help direct precision medicine screenings of LUAD patients, thus possibly improving their prognoses. |
| first_indexed | 2024-04-12T14:50:42Z |
| format | Article |
| id | doaj.art-614633b2cb524c8995cee4cca34c9542 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T14:50:42Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-614633b2cb524c8995cee4cca34c95422022-12-22T03:28:28ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-06-011310.3389/fimmu.2022.877896877896Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic ImplicationsFeng Wang0Xuan Gao1Xuan Gao2Peiyuan Wang3Peiyuan Wang4Peiyuan Wang5Hao He6Peng Chen7Zhentian Liu8Yujie Chen9Hang Zhou10Weijie Chen11Xin Yi12Xuefeng Xia13Shuoyan Liu14Shuoyan Liu15Shuoyan Liu16Department of Thoracic oncology surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, ChinaState Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, ChinaGenePlus-Shenzhen Clinical Laboratory, Shenzhen, ChinaDepartment of Thoracic oncology surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, ChinaFujian Key Laboratory of Translational Cancer Medicine, Fuzhou, ChinaDepartment of Translational Medicine, GenePlus-Shenzhen Clinical Laboratory, Shenzhen, ChinaDepartment of Thoracic oncology surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, ChinaDepartment of Thoracic oncology surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, ChinaDepartment of Translational Medicine, Geneplus-Beijing Institute, Beijing, ChinaDepartment of Thoracic oncology surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, ChinaDepartment of Thoracic oncology surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, ChinaDepartment of Thoracic oncology surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, ChinaDepartment of Translational Medicine, Geneplus-Beijing Institute, Beijing, ChinaDepartment of Translational Medicine, Geneplus-Beijing Institute, Beijing, ChinaDepartment of Thoracic oncology surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, ChinaFujian Key Laboratory of Translational Cancer Medicine, Fuzhou, ChinaDepartment of Translational Medicine, GenePlus-Shenzhen Clinical Laboratory, Shenzhen, ChinaThe six transcriptomic immune subtypes (ISs) (C1 - C6) were reported to have complex and different interplay between TME and cancer cells in TCGA (The Cancer Genome Atlas) pan-cancer cohort. Our study specifically explored how the consequence of interplay determines the prognosis and the response to therapy in LUAD cohorts. Clinical and molecular information of LUAD patients were from TCGA and Gene Expression Omnibus (GEO). The immune cell populations and gene/pathway enrichment analysis were performed to explore the molecular differences among the C3 IS and other ISs in the LUAD population. The proportion of C3 inflammatory IS was identified as the most common IS in both TCGA (N = 457) and GEO (N = 901) cohorts. The C3 IS was also found to be the most accurate prognostic subtype, which was associated with significantly longer OS (p <0.001) and DFS (p <0.001). The C3 IS presented higher levels of CD8 T, M1 macrophage, and myeloid dendritic cells, while lower levels of M2 macrophages and cancer-associated fibroblast cells. Moreover, the C3 subtype was enriched in the antigen process and presenting, interferon-gamma response, T cell receptor signaling, and natural killer cell-mediated cytotoxicity pathways than C1/C2. In contrast, the C1/C2 presented greater activation of pathways related to the cell cycles, DNA repair, and p53 signaling pathways. The immune-related C3 IS had a great ability to stratify the prognosis of LUAD, providing clues for further pathogenic research. This classification might help direct precision medicine screenings of LUAD patients, thus possibly improving their prognoses.https://www.frontiersin.org/articles/10.3389/fimmu.2022.877896/fulllung adenocarcinomaprognostic signatureTMEimmune subtypes (ISs)precision medicine |
| spellingShingle | Feng Wang Xuan Gao Xuan Gao Peiyuan Wang Peiyuan Wang Peiyuan Wang Hao He Peng Chen Zhentian Liu Yujie Chen Hang Zhou Weijie Chen Xin Yi Xuefeng Xia Shuoyan Liu Shuoyan Liu Shuoyan Liu Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications Frontiers in Immunology lung adenocarcinoma prognostic signature TME immune subtypes (ISs) precision medicine |
| title | Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications |
| title_full | Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications |
| title_fullStr | Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications |
| title_full_unstemmed | Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications |
| title_short | Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications |
| title_sort | immune subtypes in luad identify novel tumor microenvironment profiles with prognostic and therapeutic implications |
| topic | lung adenocarcinoma prognostic signature TME immune subtypes (ISs) precision medicine |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.877896/full |
| work_keys_str_mv | AT fengwang immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT xuangao immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT xuangao immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT peiyuanwang immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT peiyuanwang immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT peiyuanwang immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT haohe immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT pengchen immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT zhentianliu immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT yujiechen immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT hangzhou immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT weijiechen immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT xinyi immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT xuefengxia immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT shuoyanliu immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT shuoyanliu immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications AT shuoyanliu immunesubtypesinluadidentifynoveltumormicroenvironmentprofileswithprognosticandtherapeuticimplications |